Urinary incontinence is a prevalent, although often unreported, disease within the elderly population, with consequences spanning many aspects of the patient's life. Treatments differ for each subtype of urinary incontinence: urge incontinence, stress incontinence, and incontinence associated with bladder outlet obstruction and lower urinary tract symptoms in men. Limitations in current therapies have negatively affected care for each of these subtypes, particularly in the vulnerable elderly population. An emergence of new treatment options and strategies has created opportunities to optimize care for the general population. These include the use of trospium, darifenacin, solifenacin, and duloxetine as well as the strategic use of antimuscarinic agents in conjunction with alpha adrenergic blockade in men with bladder outlet obstruction. Yet, the literature regarding use of these agents and strategies in the elderly should be carefully evaluated to determine the benefits and the unique risks posed by their use in this vulnerable population.
Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States . World J Urol.2003;20:327-336.
2.
Sier H., Ouslander J., Orzeck S.Urinary incontinence among geriatric patients in an acute-care hospital. JAMA.1987;257: 1767-1771.
3.
Herzog AR, Fultz NHPrevalence and incidence of urinary incontinence in community-dwelling populations . J Am Geriatr Soc.1990;38:273-281.
4.
Ouslander JG , Kane RL, Abrass IBUrinary incontinence in elderly nursing home patients. JAMA.1982;248:1194-1198. 5. United States Census Bureau.Annual estimates of the population for the United States, regions, and divisions, April 1, 2000 to July 1, 2004. Available at: http://www.census.gov/popest/states/tables/NST-EST2004-08.pdf. Accessed January 3, 2006.
5.
Norton PA, MacDonald LD, Sedgwick PM, Stanton SLDistress and delay associated with urinary incontinence, frequency, and urgency in women. BMJ.1988;297:1187-1189.
6.
Kim SH, Boye M., Bhattacharyya SK, Coyne K., Dhawan R.Medical visits among adults with symptoms commonly associated with an overactive bladder. BJU Int.2006;97:551-554.
7.
Hu TW, Wagner THHealth-related consequences of overactive bladder: an economic perspective . BJU Int.2005;96 (suppl 1):43-45.
8.
Brown JS, Vittinghoff E., Wyman JF, et al. Urinary incontinence: does it increase risk for falls and fractures? Study of osteoporotic fractures research group. J Am Geriatr Soc.2000; 48:721-725.
9.
Dunlop DD, Manheim LM, Sohn MW, Liu X., Chang RWIncidence of functional limitation in older adults: the impact of gender, race, and chronic conditions. Arch Phys Med Rehabil.2002;83:964-971.
10.
Reuben DB, Rubenstein LV, Hirsch SH, Hays RDValue of functional status as a predictor of mortality: results of a prospective study. Am J Med.1992;93:663-669.
11.
Keller BK, Potter JFPredictors of mortality in outpatient geriatric evaluation and management clinic patients. J Gerontol.1994;49:M246-M251.
12.
Abrams P., Cardozo L., Fall M., et al. The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Neurourol Urodyn.2002;21:167-178.
13.
Nasr SZ, Ouslander JGUrinary incontinence in the elderly. Causes and treatment options. Drugs Aging. 1998;12:349-360.
14.
Ouslander JGManagement of overactive bladder. N Engl J Med.2004;350:786-799.
15.
Katz IR, Sands LP, Bilker W., DiFilippo S., Boyce A., D'Angelo K.Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride. J Am Geriatr Soc.1998;46:8-13.
16.
Donnellan CA , Fook L., McDonald P., Playfer JROxybutynin and cognitive dysfunction. BMJ.1997;315:1363-1364.
17.
Altan-Yaycioglu R., Yaycioglu O., Aydin Akova Y, Guvel S., Ozkardes H.Ocular side-effects of tolterodine and oxybutynin, a single-blind prospective randomized trial. Br J Clin Pharmacol.2005;59:588-592.
18.
Edwards KR, O'Connor JTRisk of delirium with concomitant use of tolterodine and acetylcholinesterase inhibitors. J Am Geriatr Soc.2002;50:1165-1166.
19.
Tsao JW, Heilman KMTransient memory impairment and hallucinations associated with tolterodine use. N Engl J Med.2003;349:2274-2275.
20.
Womack KB, Heilman KMTolterodine and memory: dry but forgetful. Arch Neurol.2003;60:771-773.
21.
Lawrence M. , Guay DR, Benson SR, Anderson MJImmediate-release oxybutynin versus tolterodine in detrusor overactivity: a population analysis. Pharmacotherapy . 2000;20:470-475.
22.
Shaya FT, Blume S., Gu A., Zyczynski T., Jumadilova Z.Persistence with overactive bladder pharmacotherapy in a Medicaid population . Am J Manag Care.2005;11: S121-S129.
23.
Appell RA, Sand P., Dmochowski R., et al. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT study. Mayo Clin Proc.2001;76:358-363.
24.
Diokno AC, Appell RA, Sand PK, et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc.2003;78:687-695.
25.
Anderson RU, Mobley D., Blank B., Saltzstein D., Susset J., Brown JSOnce daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. OROS oxybutynin study group. J Urol.1999;161:1809-1812.
26.
Zinner NR, Mattiasson A., Stanton SLEfficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. J Am Geriatr Soc.2002;50:799-807.
27.
Zinner N., Gittelman M., Harris R., et al. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol.2004;171:2311-2315, quiz 2435.
28.
Rudy D., Cline K., Harris R., Goldberg K., Dmochowski R.Multicenter phase III trial studying trospium chloride in patients with overactive bladder. Urology. 2006;67:275-280.
29.
Foote J., Glavind K., Kralidis G., Wyndaele JJTreatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist. Eur Urol.2005;48:471-477.
30.
Chapple C., Steers W., Norton P., et al. A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder. BJU Int.2005;95:993-1001.
31.
Chapple CR, Martinez-Garcia R., Selvaggi L., et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol.2005;48:464-470.
32.
Chapple CR, Rechberger T., Al-Shukri S., et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int.2004 ;93:303-310.
33.
Wagg A., Wyndaele JJ, Sieber P.Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis. Am J Geriatr Pharmacother.2006;4: 14-24.
34.
Davila GW, Daugherty CA, Sanders SW, Transdermal Oxybutynin Study Group. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J Urol.2001;166:140-145.
35.
Dmochowski RR, Nitti V., Staskin D., Luber K., Appell R., Davila GWTransdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials. World J Urol.2005;23:263-270.
Dmochowski R.Improving the tolerability of anticholinergic agents in the treatment of overactive bladder. Drug Saf.2005;28:583-600.
38.
Todorova A. , Vonderheid-Guth B., Dimpfel W.Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J Clin Pharmacol.2001;41:636-644.
39.
Staskin DR, Harnett MDEffect of trospium chloride on somnolence and sleepiness in patients with overactive bladder. Curr Urol Rep. 2004;5:423-426.
40.
Diefenbach K., Arold G., Wollny A., Schwantes U., Haselmann J., Roots I.Effects on sleep of anticholinergics used for overactive bladder treatment in healthy volunteers aged > or = 50 years . BJU Int.2005;95:346-349.
41.
Novartis Pharmaceuticals.Enablex® package insert. East Hanover, NJ: February 2006.
42.
Astellas Pharma Technologies, GlaxoSmithKline.Vesicare® package insert. Norman, Okla: July 2005.
43.
Zinner N., Susset J., Gittelman M., Arguinzoniz M., Rekeda L., Haab F.Efficacy, tolerability and safety of darifenacin, an M(3) selective receptor antagonist: an investigation of warning time in patients with OAB. Int J Clin Pract.2006;60:119-126.
44.
Cardozo L., Dixon A.Increased warning time with darifenacin: a new concept in the management of urinary urgency. J Urol.2005;173:1214-1218.
45.
Maruyama S. , Oki T., Otsuka A., et al. Human muscarinic receptor binding characteristics of antimuscarinic agents to treat overactive bladder. J Urol.2006;175:365-369.
46.
Lipton RB, Kolodner K., Wesnes K.Assessment of cognitive function of the elderly population: effects of darifenacin . J Urol.2005;173:493-498.
47.
Chapple CR, Abrams P.Comparison of darifenacin and oxybutynin in patients with overactive bladder: assessment of ambulatory urodynamics and impact on salivary flow. Eur Urol.2005;48:102-109.
48.
Clemett D., Jarvis B.Tolterodine: a review of its use in the treatment of overactive bladder. Drugs Aging.2001;18:277-304.
49.
Siddiqui MA , Perry CM, Scott LJOxybutynin extendedrelease: a review of its use in the management of overactive bladder. Drugs.2004;64:885-912.
50.
Chapple C., Khullar V., Gabriel Z., Dooley JAThe effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. Eur Urol.2005;48:5-26.
51.
Hannestad YS , Rortveit G., Sandvik H., Hunskaar S., Norwegian EPINCONT study. Epidemiology of incontinence in the county of Nord-Trondelag. A community-based epidemiological survey of female urinary incontinence: the Norwegian EPINCONT Study. J Clin Epidemiol.2000;53:1150-1157.
52.
Chapple CR, Wein AJ, Artibani W., et al. A critical review of diagnostic criteria for evaluating patients with symptomatic stress urinary incontinence. BJU Int.2005;95:327-334.
53.
Katofiasc MA , Nissen J., Audia JE, Thor KBComparison of the effects of serotonin selective, norepinephrine selective, and dual serotonin and norepinephrine reuptake inhibitors on lower urinary tract function in cats. Life Sci.2002;71:1227-1236.
54.
Norton PA, Zinner NR, Yalcin I., Bump RC, Duloxetine Urinary Incontinence Study Group. Duloxetine versus placebo in the treatment of stress urinary incontinence. Am J Obstet Gynecol.2002;187:40-48.
55.
Schuessler B.What do we know about duloxetine's mode of action? Evidence from animals to humans. BJOG. 2006;113 (suppl 1):5-9.
56.
A double-blind, stratified, randomised, parallel, placebo-controlled, multi-centre study to assess the efficacy and safety of duloxetine (20 mg bid for 2 weeks escalating to 40 mg bid) for up to 12 weeks, compared to placebo, in community-dwelling elderly women > or = 65 years of age with symptoms of stress urinary incontinence or stress-predominant mixed urinary incontinence . Available at: http://clinicaltrials.gov/show/NCT00244296.
57.
Dmochowski RR, Miklos JR, Norton PA, et al. Duloxetine versus placebo for the treatment of North American women with stress urinary incontinence. J Urol.2003;170:1259-1263.
58.
Millard RJ, Moore K., Rencken R., Yalcin I., Bump RC, Duloxetine UI Study Group. Duloxetine vs placebo in the treatment of stress urinary incontinence: a four-continent randomized clinical trial. BJU Int.2004;93:311-318.
59.
van Kerrebroeck P., Abrams P., Lange R., et al. Duloxetine versus placebo in the treatment of European and Canadian
60.
women with stress urinary incontinence. BJOG.2004;111: 249-257.
61.
Mariappan P., Alhasso A., Ballantyne Z., Grant A., N'dow J. Duloxetine, a serotonin and noradrenaline reuptake inhibitor (SNRI) for the treatment of stress urinary incontinence: a systematic review. Eur Urol.2007;51:67-74.
62.
Cardozo L., Drutz HP, Baygani SK, Bump RCPharmacological treatment of women awaiting surgery for stress urinary incontinence . Obstet Gynecol.2004;104:511-519.
63.
Castro-Diaz D. , Palma PC, Bouchard C., et al. Effect of dose escalation on the tolerability and efficacy of duloxetine in the treatment of women with stress urinary incontinence . Int Urogynecol J Pelvic Floor Dysfunct.2006; ePub ahead of print.
64.
Skinner MH, Kuan HY, Skerjanec A., et al. Effect of age on the pharmacokinetics of duloxetine in women . Br J Clin Pharmacol.2004;57:54-61.
65.
Hyman MJ, Groutz A., Blaivas JGDetrusor instability in men: correlation of lower urinary tract symptoms with urodynamic findings. J Urol.2001;166:550-552, discussion 553.
66.
Abdel-Aziz KF, Lemack GEOveractive bladder in the male patient: bladder, outlet, or both?Curr Urol Rep. 2002;3:445-451.
67.
Peters TJ, Donovan JL, Kay HE, et al. The International Continence Society “benign prostatic hyperplasia” study: the bothersomeness of urinary symptoms. J Urol.1997;157:885-889.
68.
Lee JY, Kim HW, Lee SJ, Koh JS, Suh HJ, Chancellor MBComparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int.2004;94:817-820.
69.
Kaplan SA, Walmsley K., Te AETolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol.2005;174:2273-2275, discussion 2275-2276.
70.
Athanasopoulos A., Gyftopoulos K., Giannitsas K., Fisfis J., Perimenis P., Barbalias G.Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol.2003;169:2253-2256.
71.
Abrams P., Kaplan S., De Koning Gans HJ, Millard R.Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol.2006;175:999-1004, discussion 1004.
72.
Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M., Bavendam T., Guan Z.Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA.2006;296:2319-2328.
